by Greg Guenthner
Does the mere thought of buying biotech stock give you the willies?
Some of the market’s ugliest, most hated stocks have lurched back to life over the past couple weeks.
These former dogs have helped traders like you net lightning-fast gains in a matter of days—hours in some cases.
But there’s one comeback story that hadn’t popped up on our screens yet. That’s biotech. Is it time to buy again? You’re about to find out…